Pipeline

Pipeline: Value-Creating Outcomes

OP-101
OP-101 is a hydroxyl dendrimer therapeutic (HDT) with N-acetyl cysteine (NAC) that selectively targets reactive macrophages and microglia, immune cells that play key roles in directing and controlling inflammation in multiple diseases.

D-4517.2
D-4517.2 is an HDT with potent anti- angiogenic activity that crosses the blood-retinal barrier and selectively targets reactive inflammatory and retinal pigment epithelial cells. D-4517.2 has the potential to change the current treatment paradigm for neovascular age-related macular degeneration (wet-AMD) and diabetic macular edema (DME) by offering a subcutaneous route of administration rather than delivery via intravitreal injection.

OP-801
OP-801 is a hydroxyl dendrimer (HD) imaging agent that selectively targets reactive macrophages and microglia. OP-801 will allow us to visualize HD drug delivery in hard to access regions such as the brain, joints and lungs. We are currently studying OP-801’s ability to cross the blood-brain barrier in regions of neuroinflammation; this will inform HD therapeutic delivery in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer’s disease and Parkinson’s disease.

D6-B483
D6-483 is an HD imaging agent with the ability to cross the blood-brain barrier and be used in patient selection for potential neuro-oncology treatments.

Engine Rapidly Delivers Breakthrough Therapies

Engine Rapidly Delivers Breakthrough Therapies

Opening the Therapeutic Index

  • Uptake only in reactive and diseased cells (no off-target toxicity)
  • Renal excretion – no liver uptake or metabolism
  • Rapid clearance (<1-2 days in humans) with retention in cells for up to a month (less systemic exposure)
  • Human demonstration of HDT with drug that is normally toxic
  • Example
    • D-4517.2, potent anti-angiogenic agent, no observed adverse effects in humans at the therapeutically effective dose
    • HD-Aurastatin E (D-4532) did not result in observed toxicity at 10x doses of Aurastatin E that were lethal in mice after systemic administration
Opening the Therapeutic Window

Disrupting the Drug Development Paradigm

Disrupting the Drug Development Paradigm

Ability to take “failed” or toxic drugs (1000s) and repurpose them as HDTs